studies of recent FDA approvals. PROs were key to assess treatment benefit in diseases such as those related to genitourinary, digestive and musculoskeletal systems as per respective regulatory guidance.
OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]
Gnanasakthy, A., & DeMuro, C. (2016). OUTCOME ASSESSMENTS OF PRIMARY ENDPOINTS OF NEW DRUGS APPROVED BY THE FDA (2011-2015) [MEETING ABSTRACT PHP101]. Value in Health, 19(3), A275-A275. https://doi.org/10.1016/j.jval.2016.03.1962
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
OCCASIONAL PAPER
Bringing an equity-centered framework to research
OCCASIONAL PAPER
The Preschool Entitlement
OCCASIONAL PAPER
Culturally informed community engagement
Article